Bausch Health Companies (BHC) FCF Margin (2009 - 2026)
Bausch Health Companies' (BHC) quarterly FCF Margin came in at 20.79% in Q2 2026, up 1328.0% year-over-year from 1.46% in Q2 2025, and up 333.72% quarter-over-quarter from 4.79% in Q1 2026.
Analysis
Bausch Health Companies (BHC) FCF Margin (2009 - 2026) Analysis & Trends
Bausch Health Companies has disclosed FCF Margin across 18 years of filings, most recently posting 20.79% for Q2 2026.
- In Q2 2026, FCF Margin rose 1328.0% year-over-year to 20.79%; the TTM figure through Jun 2026 stood at 13.19% (up 187.0% YoY), while the FY2025 annual figure was 9.77%, down 332.0% from the prior year.
- FCF Margin came in at 20.79% for Q2 2026 at Bausch Health Companies, up from 4.79% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 20.79% in Q2 2026 to a low of 64.37% in Q3 2022.
- Average FCF Margin over 5 years is 5.75%, with a median of 9.47% recorded in 2023.
- Year-over-year, FCF Margin sank 8810 bps in 2022 and surged 7509 bps in 2023.
- Over 5 years, FCF Margin stood at 18.65% in 2022, then tumbled by 35 bps to 12.13% in 2023, then jumped by 60 bps to 19.34% in 2024, then fell by 25 bps to 14.41% in 2025, then jumped by 44 bps to 20.79% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 20.79% in Q2 2026, 4.79% in Q1 2026, and 14.41% in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | 7.41% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | 8.76% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | 3.10% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -6.52% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 20.79% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 14.76% |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 20.15% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 23.24% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.79% |
| Mar 31, 2026 | 4.79% |
| Dec 31, 2025 | 14.41% |
| Sep 30, 2025 | 11.71% |
| Jun 30, 2025 | 7.51% |
| Mar 31, 2025 | 4.25% |
| Dec 31, 2024 | 19.34% |
| Sep 30, 2024 | 13.31% |
| Jun 30, 2024 | 12.57% |
| Mar 31, 2024 | 5.99% |
| Dec 31, 2023 | 12.13% |
| Sep 30, 2023 | 10.72% |
| Jun 30, 2023 | 8.21% |
| Mar 31, 2023 | 5.50% |
| Dec 31, 2022 | 18.65% |
| Sep 30, 2022 | -64.37% |
| Jun 30, 2022 | 3.61% |
| Mar 31, 2022 | -5.68% |
| Dec 31, 2021 | -2.46% |
| Sep 30, 2021 | 23.73% |